Wako Diagnostics Liver Cancer Tests: A Patient’s Guide to Understanding AFP-L3 & DCP

Liver cancer, specifically Hepatocellular Carcinoma (HCC), is a growing global health concern. Because it often presents with few symptoms in its early, most treatable stages, proactive screening for high-risk individuals is a cornerstone of modern care. This guide explains who is at risk, the importance of surveillance programs, and how advanced diagnostic blood tests from companies like Wako Diagnostics can aid in early detection.

Understanding Your Risk: Who Needs Liver Cancer Surveillance?

Not everyone needs regular screening for liver cancer. Surveillance programs are targeted at specific high-risk groups to ensure resources are used effectively and those who need it most are protected.

The primary groups for whom major liver societies like the American Association for the Study of Liver Diseases (AASLD) recommend surveillance include:

• Patients with Cirrhosis: This is advanced scarring of the liver from any cause (viral hepatitis, alcohol, fatty liver disease).
• Chronic Hepatitis B Carriers: Even without cirrhosis, certain hepatitis B patients (e.g., those with a family history of HCC or high viral load) are at elevated risk.

The Surveillance Protocol: What to Expect

For high-risk patients, surveillance is a routine, scheduled process designed to catch abnormalities as early as possible.

• Frequency: Screening is typically performed every 6 months.
• Core Screening Tools: The standard surveillance method combines two tests:
  • Abdominal Ultrasound: An imaging test to look for masses or nodules in the liver.
  • Alpha-fetoprotein (AFP) Blood Test: A traditional tumor marker.

Beyond AFP: The Role of Advanced Biomarkers (AFP-L3 & DCP)

While AFP has been used for decades, it is not perfect. Levels can be normal in some patients with cancer and elevated in some with non-cancerous liver conditions. This is where newer, more specific biomarkers add value.

Wako Diagnostics and others offer these advanced blood tests, which are often used in conjunction with ultrasound and AFP to refine risk assessment.

Test Name (Biomarker)	What It Measures	Clinical Advantage & Role
AFP-L3 (Lens culinaris agglutinin-reactive AFP)	A specific glycoform (sugar-chain variant) of AFP.	It is a more specific marker for HCC than total AFP. An elevated AFP-L3 percentage suggests a higher likelihood that an AFP increase is due to cancer rather than benign liver inflammation.
DCP (Des-gamma-carboxy Prothrombin) Also known as PIVKA-II	An abnormal form of a protein (prothrombin) made by the liver.	It is independent of AFP, helping to detect some HCC cases that AFP misses. It is particularly useful in assessing tumor aggressiveness.

These tests are valuable tools to help doctors:

• Assess the risk of a liver nodule being cancerous.
• Monitor patients with chronic liver disease for the earliest signs of cancer development.
• Monitor for recurrence in patients who have been treated for HCC.

Liver Cancer: The Global Burden and Major Risk Factors

Hepatocellular Carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Its incidence is rising in many parts of the world, including the United States.

The primary established risk factors for developing HCC are:

• Chronic Viral Hepatitis: Hepatitis B (HBV) and Hepatitis C (HCV) infections are the most common global causes.
• Cirrhosis: From any cause, including alcohol-related liver disease and non-alcoholic fatty liver disease (NAFLD/NASH).
• Other Factors: Aflatoxin exposure (a food contaminant in some regions), certain genetic conditions, and smoking.

Frequently Asked Questions (FAQ)

1. If I have hepatitis B or C but no cirrhosis, do I need surveillance?

Recommendations vary by condition. Most patients with cirrhosis from any cause require surveillance. For chronic Hepatitis B without cirrhosis, surveillance may be recommended for specific higher-risk subgroups (like those with a family history of HCC or high viral activity). Patients with cured Hepatitis C who have advanced fibrosis (stage F3 or higher) still need surveillance. Your hepatologist or gastroenterologist can assess your individual risk.

2. Is an ultrasound enough for surveillance, or do I need the blood tests too?

Current best-practice guidelines recommend both an ultrasound and a blood test (AFP) every 6 months. Ultrasound is the primary imaging tool, but adding a tumor marker increases the overall sensitivity for detecting cancer. The newer markers (AFP-L3, DCP) are used to provide additional, more specific information when needed.

3. What does a “positive” or elevated AFP-L3 or DCP test result mean?

An elevated result does not mean you definitely have cancer. It means your risk of having HCC or developing it soon is statistically higher. It is a “red flag” that prompts your doctor to investigate further, usually with more detailed imaging like a contrast-enhanced CT scan, MRI, or a specialized liver ultrasound. It is a tool for risk stratification, not a standalone diagnosis.

4. I’m in a surveillance program. What happens if they find something?

The goal of surveillance is to find nodules when they are small (<2-3 cm). If a suspicious lesion is found, your doctor will order definitive diagnostic tests. Small, early-stage HCC has a wide range of curative treatment options, including surgical resection, liver transplantation, or local ablation therapies (destroying the tumor with heat or radiation). This is why early detection is so powerful.

5. Can these tests be used to monitor treatment?

Yes. AFP, AFP-L3, and DCP are often used as part of the follow-up after HCC treatment. A successful treatment (like surgery or ablation) should cause elevated tumor marker levels to drop to normal. A subsequent rise in these markers during follow-up can be an early sign of cancer recurrence, prompting earlier imaging and intervention.